Shanghai Allist Pharmaceuticals Co., Ltd.

Zte Corporation

Tongji University

Shanghai Allist Pharmaceuticals, Inc.

Shanghai Biomabs Pharmaceuticals Co., Ltd.

Shuhui Wang

Ming Li

Yong Wu

Huibing Luo

Huayong Zhou

Tao Lin

Ping Wu

Zhao Wu

Chuan Li

Liping Zhao

Xin Tong

Ying Kan

Kailun Zhou

The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R, R, R, R, R, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.

Pyridinylaminopyrimidine derivatives, preparation process and use thereof

Provided is an encoding and decoding method and device for data compression. The encoding method includes: adaptively selecting a constrained string mode from a plurality of preset constrained string modes; and performing, according to the selected constrained string mode, string-matching encoding on a coding block to obtain information of a constrained string encoded in the selected constrained string mode and to obtain a bitstream of a syntax element of the constrained string encoded in the selected constrained string mode.

Encoding and decoding method and device for data compression

The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R, R, R, R, R, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases. 

The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.

Fully human monoclonal antibody to VEGF, preparation method and use thereof

Growing community of inventors

Shanghai, China

Shuhui Wang